The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“The mechanism of DMF action has not been completely elucidated, but it is known to activate the nuclear-related factor 2 transcriptional pathway, which reduces oxidative cell stress, as well as to modulate nuclear factor kB, which could have anti-inflammatory effects.(87,88) Fumaric acid compounds have been used for d…”
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Sex ratio of multiple sclerosis in Canada: a longitudinal study
Orton, S.-M., Herrera, B. M., Yee, I. M., Valdar, W., Ramagopalan, S. V., Sadovnick, A. D., & Ebers, G. C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70581-6 · Cited by 921
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms
Engelhardt, B., & Ransohoff, R. M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.07.004 · Cited by 673
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., Naves, R., Han, M., Zhong, F., Castellanos, J. G., et al. (2010) · Nature Medicine · doi:10.1038/nm.2110 · Cited by 534
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
Grey matter pathology in multiple sclerosis
Geurts, J. J., & Barkhof, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70191-1 · Cited by 507
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22128 · Cited by 433
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Pathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Comi, G., Jeffery, D., Kappos, L., Montalban, X., Boyko, A., Rocca, M. A., & Filippi, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1104318 · Cited by 364
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277457.17420.b5 · Cited by 339
Multiple sclerosis and depression
Feinstein, A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511417835 · Cited by 337
Simon, J. H., Li, D. K. B., Traboulsee, A. L., Coyle, P. K., Arnold, D. L., Barkhof, F., Frank, J. A., Grossman, R. L., Paty, D. W., Radue, E. W., et al. (2006) · PubMed · Cited by 325
Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Würfel, J., Ohayon, J., Waldmann, T. A., McFarland, H. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402653101 · Cited by 315
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 303
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Jones, J. L., Phuah, C.-L., Cox, A. L., Thompson, S. A., Ban, M., Shawcross, J., Walton, A., Sawcer, S. J., Compston, A., & Coles, A. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37878 · Cited by 297
Gold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., Robinson, R., Riester, K., Rana, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62190-4 · Cited by 287
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J.-C., Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000341766.59028.9d · Cited by 282
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Shirani, A., Zhao, Y., Karim, M. E., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Gustafson, P., Petkau, J., & Tremlett, H. (2012) · JAMA · doi:10.1001/jama.2012.7625 · Cited by 263
Environmental factors and their timing in adult-onset multiple sclerosis
Handel, A. E., Giovannoni, G., Ebers, G. C., & Ramagopalan, S. V. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.1 · Cited by 263
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
Goodin, D. S., Reder, A. T., Ebers, G. C., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., DeSimone, T. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535cf6 · Cited by 249
for the AFFIRM and SENTINEL Investigators, Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0093-1 · Cited by 234
Marriott, J. J., Miyasaki, J. M., Gronseth, G., & O'Connor, P. W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1ae0 · Cited by 233
Effects of dimethyl fumarate on neuroprotection and immunomodulation
Albrecht, P., Bouchachia, I., Goebels, N., Henke, N., Hofstetter, H. H., Issberner, A., Kovacs, Z., Lewerenz, J., Lisak, D., Maher, P., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-163 · Cited by 227
Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
Kappos, L., Weinshenker, B., Pozzilli, C., Thompson, A. J., Dahlke, F., Beckmann, K., Polman, C., & McFarland, H. (2004) · Neurology · doi:10.1212/01.wnl.0000145561.08973.4f · Cited by 224
Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
Khan, O., Rieckmann, P., Boyko, A., Selmaj, K., Zivadinov, R., & GALA Study Group (2013) · Annals of Neurology · doi:10.1002/ana.23938 · Cited by 219
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bec5 · Cited by 216 · cited 1×
“8%, including 1 fatal case that led to a risk mitigation strategy with monthly platelet count monitoring), and Goodpasture syndrome (rare).(98) This secondary autoimmunity may be associated with interleukin 21.”
Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study
Pittock, S. J., McClelland, R. L., Mayr, W. T., Jorgensen, N. W., Weinshenker, B. G., Noseworthy, J., & Rodriguez, M. (2004) · Annals of Neurology · doi:10.1002/ana.20197 · Cited by 211
Fingolimod phosphate promotes the neuroprotective effects of microglia
Noda, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.12.005 · Cited by 211
Comabella, M., Lünemann, J. D., Río, J., Sánchez, A., López, C., Julià, E., Fernández, M., Nonell, L., Camiña-Tato, M., Deisenhammer, F., et al. (2009) · Brain · doi:10.1093/brain/awp228 · Cited by 206
The cost burden of multiple sclerosis in the United States: a systematic review of the literature
Adelman, G., Rane, S. G., & Villa, K. F. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.778268 · Cited by 205
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators (2013) · Annals of Neurology · doi:10.1002/ana.23863 · Cited by 203
Fingolimod-associated macular edema: Incidence, detection, and management
Jain, N., & Bhatti, M. T. (2012) · Neurology · doi:10.1212/wnl.0b013e318248deea · Cited by 202
Evidence of interferon β-1a dose response in relapsing-remitting MS: The OWIMS Study
The Once Weekly Interferon for MS Study Group (OWIMS) (1999) · Neurology · doi:10.1212/wnl.53.4.679 · Cited by 200
Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H.-P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70103-4 · Cited by 198
Emerging effects of comorbidities on multiple sclerosis
Marrie, R. A., & Horwitz, R. I. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70135-6 · Cited by 194
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H., & Wattjes, M. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215357 · Cited by 185
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Dhib-Jalbut, S. (2002) · Neurology · doi:10.1212/wnl.58.8_suppl_4.s3 · Cited by 184
Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results
Noseworthy, J. H., Wolinsky, J. S., Lublin, F. D., Whitaker, J. N., Linde, A., Gjorstrup, P., Sullivan, H. C., & the North American Linomide Investigators (2000) · Neurology · doi:10.1212/wnl.54.9.1726 · Cited by 174
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results
Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E., & Carlson, N. G. (2007) · Neurology · doi:10.1212/01.wnl.0000267662.41734.1f · Cited by 161
Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
Claussen, M. C., & Korn, T. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.02.011 · Cited by 160
Benefit-Risk Assessment of Leflunomide
Alcorn, N., Saunders, S., & Madhok, R. (2009) · Drug Safety · doi:10.2165/11316650-000000000-00000 · Cited by 157
l -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Schwab, N., Schneider‐Hohendorf, T., Posevitz, V., Breuer, J., Göbel, K., Windhagen, S., Brochet, B., Vermersch, P., Lebrun‐Frénay, C., Posevitz‐Fejfár, A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a351fb · Cited by 143
Giovannoni, G., Southam, E., & Waubant, E. L. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511433302 · Cited by 140
COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS
Salvatore, E., Morra, V. B., & Orefice, G. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab6e08 · Cited by 121
Sørensen, P. S., Lycke, J., Erälinna, J.-P., Edland, A., Wu, X., Frederiksen, J. L., Oturai, A. B., Malmeström, C., Stenager, E., Sellebjerg, F. T., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70144-2 · Cited by 119
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
Birnbaum, G., Cree, B., Altafullah, I., Zinser, M., & Reder, A. T. (2008) · Neurology · doi:10.1212/01.wnl.0000319698.40024.1c · Cited by 117
Defining and scoring response to IFN-β in multiple sclerosis
Sormani, M. P., & Stefano, N. D. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.146 · Cited by 114
Wu, N., Minden, S. L., Hoaglin, D. C., Hadden, L. S., & Frankel, D. (2007) · Journal of Health and Human Services Administration · doi:10.1177/107937390703000306 · Cited by 105
Manufacturer's Response to Case Reports of PML
Sweetser, M. T., Dawson, K. T., & Bozic, C. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300283 · Cited by 99
Goodin, D. S., Traboulsee, A. L., Knappertz, V. A., Reder, A. T., Li, D., Langdon, D. W., Wolf, C., Beckmann, K., Konieczny, A., Ebers, G. C., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301178 · Cited by 94
Edan, G., Comı, G., Page, E. L., Leray, E., Rocca, M. A., Filippi, M., & for The French-Italian Mitoxantrone Interferon-beta-1b Trial Group (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.229724 · Cited by 93
JC virus antibody status underestimates infection rates
Berger, J. R., Houff, S. A., Gurwell, J. A., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23893 · Cited by 84
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod
Ratchford, J. N., Costello, K., Reich, D. S., & Calabresi, P. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735d00 · Cited by 84
Personalized medicine in multiple sclerosis: hope or reality?
Derfuss, T. J. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-116 · Cited by 70
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
Bushnell, S. E., Zhao, Z., Stebbins, C. C., Cadavid, D., BUKO, A. M., Whalley, E. T., Davis, J. A., Versage, E. M., Richert, J. R., Axtell, R. C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318259e123 · Cited by 69
JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
Major, E. O., Frohman, E. M., & Douek, D. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1214233 · Cited by 69
Concepts of induction and escalation therapy in multiple sclerosis
Rieckmann, P. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70012-7 · Cited by 68
Switching from natalizumab to fingolimod: an observational study
Sempere, Á. P., Martín-Medina, P., Ruiz, L. B., et al. (2013) · Acta Neurologica Scandinavica · doi:10.1111/ane.12082 · Cited by 58
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis
Wiese, M. D., Rowland, A., Polasek, T. M., Sorich, M. J., & O’Doherty, C. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.800483 · Cited by 51
Fox, E., Sullivan, H. C., Gazda, S. K., Mayer, L., O’Donnell, L., Melia, K. R., & Lake, S. L. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03507.x · Cited by 50
Sheridan, J. P., Zhang, Y., Riester, K. A., Tang, M. T., Efros, L., Shi, J. D., Harris, J. M., Vexler, V. S., & Elkins, J. S. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511414755 · Cited by 50
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
Edan, G., & Page, E. L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0065-y · Cited by 41
Rudick, R. A., Rani, M. R. S., Xu, Y., Lee, J.-C., Na, J., Shrock, J., Josyula, A., Fisher, E., & Ransohoff, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019262 · Cited by 40
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
Hegen, H., Schleiser, M., Gneiss, C., Pauli, F. D., Ehling, R., Kuenz, B., Lutterotti, A., Berger, T., & Deisenhammer, F. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511426738 · Cited by 36
Present and Emerging Therapies for Multiple Sclerosis
Freedman, M. S. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000433288.30715.e3 · Cited by 27
Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
Wingerchuk, D. M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.333 · Cited by 23
Self-citationA method for evaluating treatment switching criteria in multiple sclerosis
Healy, B. C., Glanz, B. I., Stankiewicz, J., Buckle, G. J., Weiner, H. L., & Chitnis, T. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379245 · Cited by 20
The “Poison Chair” Treatment for Multiple Sclerosis
Ropper, A. H. (2012) · New England Journal of Medicine · doi:10.1056/nejme1209169 · Cited by 14
Combination therapy in MS—still a valid strategy
Kieseier, B. C., & Stüve, O. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.164 · Cited by 9
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Choi, I. Y., Piccio, L., Childress, P., Bollman, B., Ghosh, A., Brandhorst, S., Suarez, J., Michalsen, A., Cross, A. H., Morgan, T. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.009 · Cited by 505
White matter and cognition: making the connection
Filley, C. M., & Fields, R. D. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00221.2016 · Cited by 443
Atkins, H. L., Bowman, M., Allan, D., Anstee, G., Arnold, D. L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30169-6 · Cited by 325
Effector T Cells in Multiple Sclerosis
Kaskow, B. J., & Baecher-Allan, C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029025 · Cited by 314
Tourbah, A., Lebrun-Frenay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., De Sèze, J., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 302
Metadata
- Authors
- Wingerchuk, D. M., & Carter, J. L.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 89
- Issue
- 2
- Pages
- 225-240
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2042166711
- Cited by
- 416
- References
- 116
- FWCI
- 36.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.